Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to assess the steady-state pharmacokinetics of carbamazepine (CBZ) at 200 mg or 100 mg
twice daily, depending on tolerability, and administered alone and in combination with
tipranavir/ritonavir (TPV/r) after a single dose (500/200 mg) and at steady-state (500/200 mg
twice-daily)